Outspoken former pharmaceutical executive Martin Shkreli will serve seven years in prison, a sentence handed down Friday following securities fraud convictions related to two hedge funds and a drug company that he once ran.
The judge in the case said Shkreli... Read more »
[Updated 3/13/18 1:07 pm. See below.] If a shopper interacts with technology in a typical grocery store, it’s usually at the very end—as they are paying for their items.
That could be about to change, though. “Scanning loyalty cards... Read more »
Trump administration health officials were out on the stump this week, talking tough about drug prices and healthcare value, encouraging the private sector to take the lead but letting everyone know the federal government is willing to push.
In the debate... Read more »
When you’re trying to put the past behind you and make a fresh start, it doesn’t hurt to have $1.4 billion in your pocket.
Travis Kalanick, the Uber co-founder who was pressed to resign as CEO during a year of turmoil... Read more »
We’ve all heard the cliche about reading Playboy only for its articles, but it turns out that the magazine really does have some stellar reporting. On Monday, Playboy posted an article that brings some validation to southeast Michigan’s role in the... Read more »
[Editor’s note: This is part of a series of stories examining entrepreneurship on MIT’s campus and beyond.]
When Escher Reality announced in February that it had been acquired by Niantic, the augmented reality company that created Pokémon Go, it... Read more »
The rapid growth of cancer cells actually damages them, leading them to rely on internal repair mechanisms. Scientists are finding ways to disrupt these repair features to fight the disease, and their research is leading to a growing crop of startups.... Read more »
The cholesterol brawl is heating up again.
A pair of next-generation cholesterol-lowering drugs known as PCSK9 inhibitors came to market in 2015 and have since struggled to gain traction. Now Ann Arbor, MI-based biotech Esperion Therapeutics (NASDAQ: ESPR) thinks it... Read more »
Atomwise, a San Francisco startup that’s using artificial intelligence to hunt for compounds that could make effective new drugs, announced today that it raised a $45 million Series A round.
The small company, founded in 2012, mines the accumulated data... Read more »